• Ana L Basquiera, Mercedes J García, Juliana Martinez Rolón, Julieta Olmedo, Julia Laviano, Rubén Burgos, Gastón Caeiro, Guillermina Remaggi, Pablo Raña, Mariano Paoletti, Carlos M González, Isolda Fernández, Astrid Pavlovsky, Maria A Perusini, Andrea Rodriguez, Luciana Guanchiale, Analia Carvani, Laura Mandrile, Flavia Figueroa, Angeles Vicente Reparaz, Patricia N Fragapane Mathus, Gonzalo Garate, María E Fauque, Gustavo Kantor, Soledad Cruset, Jacqueline S Gonzalez Lorch, Milagros Szelagowski, María P Giarini, Natalia Oliveira, María C García, María V Ventriglia, Patricio H Pereyra, Daniel R Gutierrez, Gustavo Kusminsky, Josefina Troccoli, María J Freitas, Santiago Cranco, Natalia Del V Sanchez, Irene Rey, María E Funes, Sol Jarchum, Julian Freue, Augusto Miroli, Osvaldo Guerrero, Lisa López Ares, Reinaldo Campestri, Victor Bove, Graciela N Salinas, María Cabrejo, Jorge H Milone, Soledad Zabaljauregui, Daniel Gotta, Juan Carlos Dupont, and German Stemmelin.
• Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail: ana.basquiera@hospitalprivado.com.ar.
• Medicina (B Aires). 2021 Jan 1; 81 (4): 536-545.

AbstractIndividuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.

10 keywords...

hide…